Companies like NBY can't charge the kind of exorbitant
Companies like NBY can't charge the kind of exorbitant prices for over-the-counter minor-annoyance dry-eye eyewashes as they can for prescription drugs, because people have to pay out of their own pockets for over-the-counter drugs.
There will be lots of competition for anti-bacterial eyewashes, too.
How much competition will there be for a novel compound that can heal the lesions of ulcerative proctitis and possibly (when the pill formulation is finished) of other types of ulcerative intestinal diseases? Do you think that it's going to be priced the same as over-the-counter eyewash, when it will be by prescription and people's insurance will pay for it?
Is Brilacidin oral rinse for oral mucositis going to be any more expensive than a bottle of eyewash? What's more serious, dry eyes, or oral mucositis that puts people into the hospital?
What about a treatment for some kinds of cancer? Will that cost someone more than walking into Walgreen's for a bottle of eyewash?
Comparing the cost of a bottle of eyewash from a retail store with the price of prescription drugs for life-threatening illnesses is absolutely absurd. But that's the kind of nonsense I expect from the kind of basher who posts lies under many identities.
4
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Propane Power Play in Florida's Market Here's a little tune you don't hear every day: two local businesses tangoing to the beat of expansion without making a public peep about the price. Palmdale Propane, a powerhouse under the Palmdale Oil umbrella, just snapped up Affordable Gas, a local player from Belle Glade, Florida. This acquisition strengthens its grip on the...
Continue Reading
Anticipation Builds for Flex LNG's Upcoming Q3 Reveal The air's thick with expectation as Flex LNG gears up to lay its cards on the table for the third quarter of 2026. Come November 11, the company will spill the beans on its financial dance over the last few months, promising to unfurl the numbers early in the morning like a farmer checking crops at dawn—07:00 CET...
Continue Reading
OppFi's Third Quarter Performance Unpacked OppFi's recent third-quarter disclosures should get investors pondering. They've launched a new line of credit product, plugging a gap in their service portfolio, and aimed to widen their customer net. Their targeted share repurchase of $6.7 million in stock isn't small potatoes either, showing a vote of confidence in their own...
Continue Reading
How Tenax Landed in Hot Water Right off the bat, Tenax's world seems to revolve around a miracle drug called levosimendan. Now, the kicker here is what they promised and what reality threw back. We're talking about a pharmaceutical company whose tall tales supposedly cloaked the true nature of TNX-103's effectiveness—or the lack thereof. A whole class action lawsuit's...
Continue Reading
FirstLight Celebrates a Major Milestone FirstLight Home Care just hit a big milestone, reaching a whopping 300 locations. That's not just a feather in their cap; it's a sign that their approach to senior care is resonating with communities across the map. The company is kicking off a celebration tour, cleverly dubbed the Best Days Tour, highlighting each step forward with...
Continue Reading
You don’t just wander into the White House and leave unimpressed, not if you're someone who lived it like David Hume Kennerly. Imagine stepping behind those gates and through history's lens, capturing moments few had the privilege to see. Kennerly's debut as the Chief White House Photographer was at a turning point in America, just after the Nixon saga collapsed in...
Continue Reading
ReachWell's Fresh Approach: A New Era Begins Become the whisper in the wind reaching ears far and wide—enter the new ReachWell. Sounds lofty? Well, it's shooting for the stars here, folks. This isn’t just some tech upgrade. It’s a whole new brand identity and a refreshed sense of purpose. These guys have tossed everything back on the drawing board, unveiling a...
Continue Reading
Payout Boost for Income-Hungry Investors You know, it ain't every day you hear about dividend increases across the board. But Infrastructure Capital Advisors, that investment management powerhouse, is dishing out more dough to its investors through a dividend uptick. They're bumping up the payouts on not just one, but four of their ETFs: Bond Income ETF (BNDS), Equity...
Continue Reading
Behind the Unsolicited Offer Folks, it looks like Wendy's (NASDAQ:WEN) got itself mixed up in some high-stakes shenanigans. An unsolicited, non-binding proposal slammed into them, courtesy of the Investor Group led by Trian Partners, Flynn Group LP, BlueFive Capital, and Sixth Street Partners, itching to scoop up every last piece of Wendy’s stock they ain't already...
Continue Reading
Breaking Down Silos in Lab Environments When it comes to the controlled chaos of laboratory operations, data integrity is the name of the game. We're talking about a new way of doing things that doesn't demand a physics degree just to connect the dots between gizmos and databases. Enter LabWare Loop, a solution that's rewriting the data playbook by linking multi-vendor...
Continue Reading
Top 5 Most Recently Viewed Articles
Fractyl Health and Bariendo Collaborate on Innovative Solutions Fractyl Health, Inc. (NASDAQ: GUTS), a company dedicated to pioneering new approaches to obesity treatment, has entered into an exciting partnership with Bariendo Inc., an all-in-one obesity care platform. This collaboration is a proactive step aimed at exploring the future of Fractyl’s investigational...
Continue Reading
Insights into Medpace's Recent Stock Downgrade Recently, Baird has reassessed its perspective on Medpace Holdings Inc. (NASDAQ: MEDP) by downgrading the stock rating from Outperform to Neutral. Alongside this change, they reduced the price target significantly from $413 to $349. This shift reflects the evolving challenges Medpace faces, despite their historical success in...
Continue Reading
Travere Therapeutics Stock Performance Shines In a remarkable display of market confidence, Travere Therapeutics Inc. (TVTX) stock has reached a significant milestone by hitting a 52-week high of $18.63. This achievement reflects an impressive 171.22% increase in stock price over the past year, showcasing a period of substantial growth for the company. Investors have...
Continue Reading
Cizzle Brands Debuts on Cboe Canada Cboe Canada has recently welcomed Cizzle Brands Corporation as it makes its public markets debut, introducing an exciting chapter for the Canadian-based company specializing in sports nutrition. This debut under the trading symbol CZZL signifies a significant milestone as Cizzle seeks to expand its reach in the competitive market of...
Continue Reading
Concerns Over Self-Driving Cars in Atlanta As autonomous vehicles continue to grab headlines, Attorney Amy Witherite, a renowned traffic safety expert, has voiced significant concerns regarding their impending arrival in Atlanta. Recently, numerous incidents across various cities have illuminated the potential hazards associated with these self-driving cars. From...
Continue Reading